Patient characteristics and study design. (A) Schematic of treatment timeline and response assessments. (B) Kaplan-Meier curve showing progression-free survival of patients included in the analysis. (C) Number of patients with complete response (CR; green bars), PR (blue bars), SD (yellow bars), or PD (orange bars) at each response assessment time point by PET/CT scan for patients who are classified as durable Rs at 12 months (top) or NRs at or before 12 months (bottom). (D) Table shows MRD detection in patient-matched and -unmatched tests. Bar chart depicts the number of patient-unmatched MRD tests that were positive vs negative for MRD. Axi-cel, axicabtagene ciloleucel; Flu/Cy, fludarabine/cyclophosphamide; SD, stable disease.